• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: What Were the Most Important Biosimilar Findings Presented at ASCO?

Article

Diverse findings on biosimilar safety and savings were presented at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting.

Which of these biosimilar presentations at ASCO was most important?

For patients receiving myelosuppressive chemotherapy for breast and lung cancer, same-day pegfilgrastim to combat febrile neutropenia is safe and effective.
In real-world studies, the trastuzumab biosimilars Kanjinti and Zedora demonstrate comparable safety vs Herceptin for breast and gastrointestinal cancer.
The Oncology Care Model lowers use of supportive-care medications and boosts filgrastim biosimilar use.
Oncologists’ use of 3 biosimilars soared from 2019 to 2020.
Texas Oncology’s automatic biosimilar switching program led to single-month savings of $4 million (21%) among 460 health care practitioners.
Related Videos
Prerakkumar Parikh, PharmD
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Julie Reed
Julie Reed, MS
Julie Reed, executive director of the Biosimilars Forum
Ryan Haumschild, PharmD, MS, MBA
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
andre harvin
Related Content
© 2024 MJH Life Sciences

All rights reserved.